Related by context. All words. (Click for frequent words.) 76 metastatic disease 71 prostate cancer 71 metastatic cancer 71 HER2 positive breast cancer 71 prostate cancer CRPC 70 metastatic 68 castration resistant prostate cancer 68 metastatic breast cancer 68 metastatic renal cell carcinoma 68 prostate cancers 68 colorectal cancer 68 PCa 67 recurrent prostate cancer 67 metastatic RCC 67 distant metastases 67 tumor recurrence 67 malignant pleural mesothelioma 67 NSCLC 67 lung tumors 67 localized prostate cancer 66 pancreatic adenocarcinoma 66 bladder cancers 66 tumors 66 prostate cancer CaP 66 ovarian cancer 65 liver metastases 65 metastases 65 stage IIIB 65 distant metastasis 65 bladder cancer 65 renal cell carcinoma 65 carcinoma 65 bone metastasis 64 HER2 positive 64 breast tumors 64 CaP 64 leukemia AML 64 HNSCC 64 adenoma 64 medullary thyroid cancer 64 prostate adenocarcinoma 64 neoadjuvant chemotherapy 64 colon cancer 64 chemoradiotherapy 64 epithelial ovarian cancer 64 hormone refractory prostate cancer 64 pancreatic cancer 63 gastric cancer 63 IV NSCLC 63 pancreatic cancers 63 prostate cancer PCa 63 clinically localized prostate 63 prostate tumors 63 melanoma 63 metastatic gastric 63 lung metastases 62 hepatocellular carcinoma 62 neoadjuvant therapy 62 micrometastases 62 seminoma 62 prostate tumor 62 endometrial cancer 62 colorectal cancer CRC 62 acute myelogenous leukemia AML 62 differentiated thyroid 62 cell lung cancer 62 breast cancer recurrence 62 malignancy 62 prostate cancer mCRPC 62 nonsmall cell lung cancer 62 colorectal carcinoma 62 biochemical recurrence 62 metastatic tumors 62 disease progression 62 Hepatocellular Carcinoma HCC 62 breast carcinoma 62 fallopian tube carcinoma 62 recurrent glioblastoma multiforme 62 metastatic colon cancer 62 metastatic melanoma 62 metastatic pancreatic cancer 62 unresectable 61 chronic lymphocytic leukemia CLL 61 soft tissue sarcomas 61 malignant melanoma 61 metastatic colorectal cancer 61 ovarian tumors 61 gastrointestinal stromal tumors 61 recurrent ovarian cancer 61 metastatic lung cancer 61 operable breast cancer 61 breast cancers 61 brain metastases 61 chemoradiation 61 HER2 positive metastatic breast 61 AA amyloidosis 61 neuroendocrine tumors 61 lung cancer 61 adenocarcinoma 61 prostate cancer HRPC 61 metastatic malignant melanoma 61 basal cell carcinoma BCC 61 ovarian carcinoma 61 metastatic bladder 61 multiple myeloma 61 mRCC 61 castrate resistant prostate cancer 61 recurrent NSCLC 61 neoplasia 61 preoperative chemotherapy 61 PSADT 61 epithelial tumors 60 androgen deprivation 60 endometrial cancers 60 androgen deprivation therapy 60 pancreatic NET 60 Barrett esophagus 60 relapsed ovarian cancer 60 adenocarcinomas 60 lymph node metastases 60 prostate carcinoma 60 cystectomy 60 superficial bladder cancer 60 adjuvant radiotherapy 60 unresectable stage 60 locoregional 60 gastrointestinal stromal tumors GIST 60 grade gliomas 60 prostrate cancer 60 lobular carcinoma 60 advanced unresectable 60 serous ovarian cancer 60 renal carcinoma 60 androgen independent 60 hepatocellular carcinoma HCC 60 colorectal liver metastases 60 bone metastases 60 breast cancer 60 cervical carcinoma 60 metastatic colorectal 60 epithelial ovarian 60 HER2 negative 60 malignancies 60 metastatic NSCLC 60 lymphoma 60 advanced NSCLC 60 gastrointestinal stromal tumor GIST 60 hormone deprivation 59 cutaneous melanoma 59 colorectal cancers 59 peritoneal cancer 59 GISTs 59 CMV disease 59 solid tumors 59 IV metastatic melanoma 59 melanomas 59 prostate cancer AIPC 59 hormone receptor positive 59 Metastatic 59 non squamous NSCLC 59 situ CIS 59 rectal cancer 59 mCRC patients 59 squamous cell carcinoma SCC 59 peritoneal carcinomatosis 59 malignant lymphoma 59 hormone LHRH agonist 59 EBRT 59 cell carcinomas 59 carcinoid cancer 59 cancers 59 allogeneic stem cell 59 renal tumors 59 advanced adenomas 59 cancer 59 liver cancer 59 biliary tract cancer 59 tumor shrinkage 59 CIN3 59 glioblastoma 59 resectable 59 BRAF mutation 59 cabazitaxel 59 colorectal tumors 58 castrate resistant 58 pancreatic carcinoma 58 trastuzumab 58 decitabine 58 HCV infected 58 lung cancers 58 cervical lesions 58 cholangiocarcinoma 58 vandetanib 58 LHRH receptor positive 58 HER2 overexpression 58 uveal melanoma 58 leukemia CLL 58 prostate specific 58 squamous cell lung cancer 58 KRAS mutation 58 docetaxel chemotherapy 58 systemic lupus erythematosus SLE 58 osteosarcoma 58 Carcinoma 58 grade cervical intraepithelial 58 metastatic castration resistant 58 ovarian cancers 58 HRPC 58 HER2 positive cancers 58 follicular lymphoma 58 relapsed leukemia 58 thymoma 58 lymphocytic leukemia 58 metastatic cancers 58 endometrial hyperplasia 58 hepatocellular cancer 58 rectal carcinoma 58 olaparib 58 invasive breast cancer 58 pancreatic neuroendocrine tumors 58 node metastases 58 squamous cell cancer 58 pre cancerous lesions 58 abiraterone 58 cisplatin chemotherapy 58 SHPT 58 pleural mesothelioma 58 ductal breast cancer 58 hormone refractory 58 unresectable tumors 58 TACE 58 carcinoid tumors 58 adjuvant therapy 58 cell carcinoma 58 gastrointestinal stromal tumor 58 neoplasm 58 recurrent GBM 58 advanced epithelial ovarian 58 tumor 58 squamous cell 58 carcinoid 58 vinorelbine 58 lymphoma CTCL 58 ADPKD 58 HER2 + 58 biochemical relapse 58 luteinizing hormone releasing 58 melanoma tumors 58 metastatic ovarian cancer 57 medically inoperable 57 lupus nephritis 57 adenomas 57 gefitinib Iressa 57 metastatic GIST 57 lymphomas 57 cancer mCRC 57 micrometastasis 57 acute myeloid leukemia 57 lymph node involvement 57 adjuvant radiation 57 advanced adenoma 57 oropharyngeal cancer 57 cisplatin resistant 57 sarcoma 57 tumors GIST 57 heavily pretreated 57 SCCHN 57 Malignant Melanoma 57 NMIBC 57 AA Amyloidosis 57 histologically confirmed 57 external beam radiotherapy 57 urothelial cancer 57 invasive carcinoma 57 taxane therapy 57 esophageal cancer 57 recurrent metastatic 57 metachronous 57 gastric cancers 57 esophageal cancers 57 glioblastomas 57 DLBCL 57 colorectal adenoma 57 precancerous lesions 57 nonmetastatic 57 mutated KRAS 57 GnRH agonists 57 neoadjuvant 57 tumor progression 57 metastatic malignant 57 metastatic kidney 57 goserelin 57 invasive bladder 57 Androgen deprivation therapy 57 premalignant 57 Neoadjuvant 57 neoadjuvant treatment 57 leukaemias 57 Waldenstrom macroglobulinemia 57 non metastatic osteosarcoma 57 liver fibrosis 57 situ LCIS 57 mucinous 57 GIST 57 BCG refractory 57 ximelagatran 57 Glioblastoma Multiforme 57 gastric adenocarcinoma 57 squamous cell carcinoma 57 malignant growths 57 locoregional recurrence 57 recurrent glioblastoma 57 anaplastic 57 GBM tumors 57 leukemia ALL 57 free survival PFS 56 chronic lymphocytic leukemia 56 refractory ovarian cancer 56 astrocytoma 56 occult metastases 56 Irinotecan 56 glioblastoma multiforme GBM 56 intestinal metaplasia 56 bortezomib 56 hypercalcemia 56 resected 56 sunitinib 56 Hodgkin lymphoma NHL 56 stage IIIB IV 56 liver metastasis 56 nonmelanoma skin cancers 56 minimally symptomatic 56 renal cell carcinomas 56 grade glioma 56 pre cancerous polyps 56 chemotherapy cisplatin 56 bladder carcinoma 56 colorectal neoplasms 56 IV melanoma 56 nasopharyngeal carcinoma 56 Amrubicin 56 metastatic breast 56 chronic periodontitis 56 pT3 56 metastatic castrate resistant 56 pancreatic tumor 56 EUS FNA 56 rectal cancers 56 adjuvant chemotherapy 56 pT2 56 osteosarcomas 56 pCR 56 AVODART 56 esophageal carcinoma 56 CLL 56 endocrine therapy 56 Mantle Cell Lymphoma 56 relapsed MM 56 stage IIIA 56 carcinomas 56 Adjuvant chemotherapy 56 esophageal adenocarcinoma 56 mammary tumors 56 colon tumors 56 Cholangiocarcinoma 56 idiopathic pulmonary fibrosis IPF 56 CLL cells 56 MGUS 56 imatinib Gleevec 56 metastatic lesions 56 fibroadenomas 56 irinotecan chemotherapy 56 BRCA mutations 56 Doxil ® 56 breast carcinomas 56 refractory multiple myeloma 56 FOLFOX4 56 ductal adenocarcinoma 56 cetuximab 56 Prostate Specific Antigen PSA 56 prognostic indicator 56 histologically 56 gastrointestinal cancers 56 glufosfamide 56 EGFR expressing 56 neoplastic cells 56 EGFR mutation 56 nonmetastatic prostate cancer 56 hepatocellular carcinomas 56 HGPIN 56 stage IIIb IV 56 lung metastasis 56 choroidal melanoma 56 relapsing remitting multiple sclerosis 56 curable cancers 56 radical prostatectomy RP 56 systemic scleroderma 56 PTLD 56 curative resection 56 atypical hyperplasia 56 oesophageal cancer 56 pancreatic tumors 55 atherosclerotic lesions 55 Acute Myelogenous Leukemia AML 55 urothelial carcinoma 55 hematological cancers 55 urothelial bladder cancer 55 paraganglioma 55 acute promyelocytic leukemia 55 alkylating agents 55 serum PSA 55 chemoresistant 55 squamous cell carcinomas 55 PNET 55 PROVENGE 55 depsipeptide 55 thyroid nodules 55 T2DM 55 abiraterone acetate 55 antibody MAb 55 Myelodysplastic Syndrome MDS 55 HGS ETR1 55 B Cell Lymphoma 55 zoledronic acid 55 lymph node 55 estrogen receptor ER 55 angiosarcoma 55 cardiotoxicity 55 skeletal metastases 55 DFMO 55 carcinoid tumor 55 adenomatous 55 precancerous cervical lesions 55 Tavocept 55 estrogen receptor negative 55 axitinib 55 androgen suppression therapy 55 erlotinib Tarceva ® 55 Bortezomib 55 sorafenib 55 anti androgen 55 non squamous 55 proliferative diabetic retinopathy 55 alveolar rhabdomyosarcoma 55 advanced metastatic prostate 55 antiangiogenic therapy 55 epirubicin 55 myelofibrosis 55 Gleevec resistant 55 radical prostatectomy 55 specific antigen 55 transurethral resection 55 premalignant lesions 55 colorectal adenomas 55 metastatic HER2 positive 55 resistant ovarian cancer 55 precursor lesions 55 ErbB2 positive 55 cytoreductive surgery 55 mutated KRAS gene 55 Glioblastoma 55 basal cell carcinomas 55 EFAPROXYN 55 alkylating agent 55 Metastatic breast cancer 55 relapsing MS 55 estrogen receptor positive 55 estramustine 55 neuroendocrine cancers 55 metastatic neuroendocrine tumors 55 lymph node metastasis 55 IGF 1R 55 testicular cancers 55 ductal carcinomas 55 Cell Lung Cancer 55 breast lesions 55 Degarelix 55 sentinel node 55 myeloablative 55 metastasis 55 basal cell cancers 55 myelodysplastic syndrome MDS 55 LHRH agonists 55 gastric carcinoma 55 cancerous enlargement 55 metastatic basal cell 55 pre cancerous growths 55 Carcinoid tumors 55 hepatic metastases 55 trabectedin 55 KRAS mutations occur 55 chronic HCV 55 IIIB NSCLC 55 5-FU/LV 55 KRAS wild 55 Chronic Lymphocytic Leukemia 55 HCV infection 55 precancerous condition 55 specific antigen PSA 55 paragangliomas 55 lung adenocarcinomas 55 bronchogenic carcinoma 55 multiple myeloma MM 55 malignant transformation 55 trastuzumab Herceptin ® 55 fibrosis 55 invasive ductal 55 taxane chemotherapy 55 PAOD 55 intestinal polyps 55 thromboembolic events 55 lobular cancer 55 OncoVEX GM CSF 55 recurrent glioblastoma multiforme GBM 55 CIN2 + 55 prostate pancreatic 55 metastatic renal cell 55 Myelodysplastic Syndrome 55 sarcomatoid 55 YONDELIS 55 ductal cancer 55 thyroglobulin 55 severe aortic stenosis 55 chemo radiotherapy 55 liver resection 55 cell lymphoma CTCL 55 squamous cell cancers 55 EGFR mutations 55 Xanafide 55 prostate tissue 55 mCRC 55 Bezielle 55 recurrent VTE 55 temsirolimus 55 axillary dissection 55 Hurthle cell 55 CYT# potent vascular disrupting 55 myeloproliferative disorders 55 cutaneous squamous cell carcinoma 54 relapsed SCLC 54 bowel cancer 54 myelofibrosis MF 54 antigen PSA 54 chlorambucil 54 B7 H3 54 papillary carcinoma 54 Vicinium TM 54 bladder tumors 54 bevacizumab Avastin 54 mycosis fungoides 54 Barrett Esophagus 54 cisplatin 54 HBeAg negative 54 basal cell nevus syndrome 54 secondary hyperparathyroidism 54 Radical prostatectomy 54 BRCA mutation carriers 54 K ras 54 pegylated liposomal doxorubicin 54 lymphocytosis 54 intratumoral injection 54 Metastatic Prostate Cancer 54 cytotoxic chemotherapy 54 transplantation HCT 54 nodal metastases 54 Nexavar sorafenib 54 exemestane 54 intravesical therapy 54 EGFr 54 symptomatic BPH 54 T1DM 54 nonalcoholic steatohepatitis NASH 54 Multiple Myeloma 54 indolent lymphomas 54 keloid scarring 54 ALND 54 anthracyclines 54 microalbuminuria 54 myeloid leukemia 54 ABCB1 54 cutaneous T cell 54 neoplasia PIN 54 FDG PET 54 prostate specific antigen 54 lung carcinomas 54 NovoTTF 54 radical cystectomy 54 glioblastoma tumors 54 prognostic factor 54 allogeneic SCT 54 undergoing radical prostatectomy 54 ZACTIMA 54 cancerous tumors 54 radiofrequency ablation RFA 54 F FDG PET 54 polyp recurrence 54 colorectal cancer liver metastases 54 chemopreventive agent 54 IV malignant melanoma 54 nodal metastasis 54 myeloproliferative disorder 54 Adjuvant therapy 54 refractory angina 54 pancreatic 54 erlotinib Tarceva 54 periodontitis 54 tamoxifen therapy 54 colon carcinoma 54 KRAS mutant tumors 54 indolent NHL 54 BRAF V#E mutation 54 refractory AML 54 colon rectal cancer 54 intravenous bisphosphonates 54 soft tissue sarcoma 54 PCNSL 54 pomalidomide 54 anthracycline taxane 54 basal cell carcinoma 54 Cystectomy 54 Acute Myeloid Leukemia 54 transitional cell carcinoma 54 azacitidine 54 pancreatic islet cell 54 follicular thyroid cancer 54 Flu Cy 54 ependymoma 54 bleomycin 54 diabetic nephropathy 54 pelvic malignancies 54 sentinel lymph node biopsy 54 pan HDAC inhibitor 54 resistant hormone refractory 54 oesophageal adenocarcinoma 54 Aplidin 54 liver transplant recipients 54 refractory prostate cancer 54 postmenopausal breast cancer 54 PSA nadir 54 pelvic lymphadenectomy 54 diabetes mellitus DM 54 ankylosing spondylitis AS 54 hyperplasia BPH 54 thyroid cancers 54 heavily pretreated patients 54 Follicular Lymphoma 54 bicalutamide 54 Adenocarcinoma 54 duodenal ulcer 54 anti angiogenic therapy 54 docetaxel 54 Rectal cancer 54 acute myeloid leukemia AML 54 papillary renal cell carcinoma 54 Proxinium TM 54 advanced metastatic renal 54 pheochromocytoma 54 myelodysplastic syndromes MDS 54 renal transplantation 54 GvHD 54 ALCL 54 hormonal therapy 54 lymph node dissection 54 cytoreduction 54 EGFR TKI 54 poorer prognosis 54 inoperable pancreatic cancer 54 neoplasias 54 smoldering myeloma 54 B CLL 54 transarterial chemoembolization 54 Cytoxan 54 MALT lymphoma 54 autoantibodies 54 gemcitabine 54 antitumor effect 54 orchiectomy 54 atypia 54 evaluable patients 54 MSMB 54 mTOR inhibitors 54 myeloproliferative diseases 54 axillary node dissection 54 Prostate cancer 54 cediranib 54 5FU 54 variceal hemorrhage 54 fallopian tube cancers 54 imatinib therapy 54 dacarbazine chemotherapy 54 hyperoxaluria 54 hormone LHRH 54 BRCA deficient 54 Acute Myelogenous Leukemia 54 radiation therapy SBRT 54 mycophenolate mofetil 54 MGd 54 benign polyps 54 remission induction 54 follicular lymphomas 54 acute leukemias 54 gliomas 54 pazopanib 54 HER2 54 concurrent chemoradiation 54 erlotinib 54 grade dysplasia 54 asymptomatic 54 Acute Myeloid Leukemia AML 54 squamous 54 allogeneic bone marrow 54 PKCi 54 FLT3 54 clodronate 54 tumor regrowth 54 benign prostatic hypertrophy 54 XELOX 54 metastatic adenocarcinoma 54 pancreatic ovarian 53 T#I [002] 53 recurrent ovarian 53 TNF antagonist 53 endometrial carcinoma 53 Duchenne Muscular Dystrophy DMD 53 relapsed refractory 53 squamous histology 53 DCIS 53 metastatic hormone refractory 53 colorectal adenocarcinoma 53 hormonal therapies 53 Her2 53 colorectal polyps 53 papillary thyroid cancer 53 transthyretin amyloidosis 53 chemoembolization 53 ocular melanoma 53 EGFRvIII 53 papillary thyroid carcinoma 53 relapsed multiple myeloma 53 metastatic pancreatic 53 seminomas 53 distal colon cancer 53 elevated triglyceride levels 53 acute GvHD 53 dasatinib 53 cyclin E 53 advanced neoplasia 53 colon polyps 53 chemotherapeutic agent 53 axillary lymph nodes 53 Hodgkin lymphoma HL 53 Papillary 53 pulmonary hypertension PH 53 HER2 expression 53 standard chemotherapy regimen 53 metastatic relapsed 53 GVAX 53 GnRH agonist 53 precancer 53 CMV infection 53 lymphadenectomy 53 chemoradiation therapy 53 renal dysfunction 53 IGF IR 53 tumor cells 53 metastatic medullary thyroid 53 Symadex 53 Gliadel Wafer 53 serum testosterone 53 paricalcitol 53 pediatric malignancies 53 cervical lymph nodes 53 basiliximab 53 temozolomide 53 gynecologic cancers 53 cancerdefine 53 undergone radical prostatectomy 53 chronic HBV infection 53 peginterferon 53 recurrent colorectal cancer 53 EGFR inhibitors 53 Decitabine 53 hematologic malignancies 53 Sjögren syndrome 53 malignant ascites 53 eribulin mesylate 53 EGF receptor 53 colon cancers 53 octreotide LAR 53 BRIM2 53 anti leukemic 53 interferon alfa 53 uPA 53 Telintra 53 synovial sarcoma 53 neoadjuvant radiation 53 lung nodules 53 Glioma 53 unresectable locally advanced 53 castration resistant 53 Acute Myeloid Leukaemia AML 53 terlipressin 53 benign prostatic hypertrophy BPH 53 elevated CRP 53 localized renal 53 Crohn disease CD 53 sipuleucel T 53 Haptoglobin 53 macroalbuminuria 53 Halaven 53 non alcoholic steatohepatitis 53 parathyroid carcinoma 53 hepatorenal syndrome 53 radioiodine therapy 53 sentinel node biopsy 53 CIN2 53 ASCUS 53 prolongs survival 53 Hodgkin Lymphoma 53 dexpramipexole 53 nutlin 3a 53 Renal Cell Carcinoma RCC 53 Stage IIIb 53 Acute myeloid leukemia 53 cytoreductive nephrectomy 53 uterine tumors 53 osteosarcoma rare 53 anastrozole 53 Testicular cancer 53 colorectal carcinomas 53 Solid Tumours 53 palliation 53 MAb 53 atherosclerotic disease 53 juvenile idiopathic arthritis 53 K ras mutations 53 subclinical hypothyroidism 53 Cetuximab 53 leiomyosarcoma 53 completely resected 53 MYCN amplification 53 angiogenesis inhibitor 53 proliferative retinopathy 53 bowel cancers 53 HER-2/neu 53 Tumours 53 neoplasms 53 sorafenib Nexavar 53 Idiopathic Pulmonary Fibrosis IPF 53 dysplasia 53 bowel polyps 53 chemotherapeutic regimens 53 colorectal neoplasia 53 Follicular lymphoma 53 Trastuzumab 53 azacytidine 53 receptor tyrosine kinase inhibitor 53 angiogenesis inhibition 53 Alemtuzumab 53 KRAS mutations 53 eribulin 53 glomerular filtration 53 contralateral breast 53 breast endometrial 53 androgen ablation 53 prostate biopsy 53 minimally symptomatic metastatic castrate 53 Dasatinib 53 hepatitis C HCV 53 invasive lobular carcinoma 53 metastatic lesion 53 T1a 53 GIST tumors 53 tumoral 53 tyrosine kinase inhibitor 53 thymalfasin 53 DAPT 53 myelofibrosis polycythemia vera 53 FSAD 53 ZYBRESTAT 53 Aspergillus infections 53 hepatoma 53 cancerous cells 53 diffuse gastric 53 varices 53 gemcitabine chemotherapy 53 PARP inhibitor 53 malignant prostate 53 gastric atrophy 53 IV bisphosphonates 53 lung pancreatic 53 radiochemotherapy 53 refractory acute myeloid 53 MAGE A3 53 chemotherapy regimen 53 lung carcinoma 53 Median survival 53 colorectal 53 ovarian 53 resected pancreatic cancer 53 Enzastaurin 53 sunitinib malate 53 Glioblastoma Multiforme GBM 53 defibrotide 53 LHRH agonist 53 transplantation HSCT 53 choroidal neovascularization 53 ischemic cardiomyopathy 53 CYC# 53 neoplastic lesions 53 non hodgkin lymphoma 53 invasive aspergillosis 53 FVIIa 53 T2D 53 esophagogastric junction 53 cirrhotic 53 leukemia APL 53 invasive candidiasis 52 systemic lupus erythematosus 52 ADAMTS# 52 neuro degenerative disease 52 alemtuzumab treated 52 NAFLD 52 bevacizumab Avastin ® 52 papillary 52 EpCAM 52 TTF Therapy 52 cervical intraepithelial neoplasia 52 malignant pleural mesothelioma MPM 52 oophorectomy 52 eosinophilic asthma 52 low expressors 52 VIDAZA 52 hepatic fibrosis 52 Non Hodgkin Lymphoma 52 vWD 52 tumor necrosis 52 dasatinib Sprycel ® 52 undetectable PSA 52 colorectal gastric 52 Surgical resection 52 liposarcoma 52 plasma uric acid 52 tumor resection 52 cytogenetic responses 52 CsA 52 Alzheimer disease AD 52 diagnosed multiple myeloma 52 malignant melanomas 52 trans retinoic acid 52 Renal Cell Carcinoma 52 nucleoside analog 52 radiation sensitizer 52 ascites 52 IL# PE#QQR 52 HuMax EGFr 52 antiestrogen 52 Lung transplantation 52 SCIg 52 non Hodgkin lymphoma 52 FOLFIRI alone 52 bladder ovarian 52 Aflibercept 52 Mitomycin C 52 octreotide 52 relapsed refractory multiple myeloma 52 Duchenne muscular dystrophy DMD 52 recurrent glioma 52 telomerase inhibition 52 myeloma 52 ELACYT 52 antihypertensive therapy 52 benign breast 52 malignant lesions 52 sentinel lymph nodes 52 chronic GVHD 52 curative therapy 52 AEG# 52 Velcade bortezomib 52 locoregional disease 52 Gefitinib 52 severe sepsis 52 orthotopic 52 acute myeloid 52 bevacizumab 52 prostate 52 Everolimus 52 lymph nodes 52 fulvestrant 52 Glioblastoma multiforme GBM 52 allogeneic hematopoietic stem cell 52 malignant polyps 52 EGFR tyrosine kinase inhibitors 52 Erlotinib 52 ERCC1 52 prostate TURP 52 HBV infection 52 surgically resectable 52 anti EGFR antibody